STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Schedule 13D/A: Casdin and Meister Disclose Double-Digit Holdings in GeneDx (WGS)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Amendment No. 9 to the Schedule 13D for GeneDx Holdings Corp. updates ownership and voting information for a group led by Eli Casdin and Keith Meister. The filing shows that Eli Casdin beneficially owns 3,599,671 shares (12.4%) and Keith A. Meister beneficially owns 3,630,826 shares (12.5%) of the Class A common stock, based on 28,726,248 shares outstanding as of July 24, 2025.

The filing attributes 3,007,164 shares (10.5%) to Casdin Partners Master Fund, L.P. and 3,058,629 shares (10.6%) to investment funds advised by Corvex Management LP. Certain reported holdings include shares issuable upon exercise of warrants and vested options (including 204,141 private placement warrants exercisable at $379.50 per share). The funds for the purchases listed were from the working capital of Casdin Partners Master Fund, L.P. Transactions in the past 60 days are reported in Exhibit B. The Amendment supplements earlier Schedule 13D filings and includes a joint filing agreement and transaction schedule as exhibits.

Positive

  • Material disclosure of ownership: Two principal reporting persons disclose >10% holdings each, providing clear transparency to the market.
  • Funding clarity: Purchases for the Casdin-held shares were made from the working capital of Casdin Partners Master Fund, L.P., with no borrowed funds used for purchases (other than ordinary working capital borrowings).
  • Exhibits filed: Joint Filing Agreement and a Schedule of Transactions (Exhibits A and B) are included to document coordination and recent transactions.

Negative

  • Potential dilution: The reported holdings include 204,141 private placement warrants exercisable at $379.50 per share and various vested options and RSU-related shares that can increase the share count.
  • Concentrated ownership: Significant shared beneficial ownership and shared voting power are concentrated among related parties, which could centralize control in a small group of affiliated holders.

Insights

TL;DR: Two activist-aligned investors report double-digit stakes, representing a material ownership position that may affect corporate governance.

The filing documents that Eli Casdin and Keith Meister, through affiliated vehicles, each hold roughly 12% of Class A stock, with institutional vehicles owning just over 10% each. These stakes are material relative to the 28.7 million shares outstanding and could influence board or strategic outcomes. The inclusion of exercisable private placement warrants and vested options increases the potential share count that these parties can control. Funding was from working capital of the Casdin fund, not borrowed funds for purchases. Overall, this is a clear, material ownership disclosure that investors should treat as a governance development.

TL;DR: Reported shared voting and dispositive power across related entities creates a concentrated, coordinated ownership bloc exceeding 10%.

The Schedule 13D/A shows shared voting and dispositive power among related entities (CMLS Holdings LLC, C-LSH LLC, M-LSH LLC, Casdin entities, and Corvex-related funds), resulting in concentrated influence. The filing identifies specific securities that expand voting potential, including private placement warrants and vested options. Exhibits confirm recent open-market transactions. The structure and level of ownership are sufficiently material to be considered impactful for governance and strategic discussions at the issuer.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


CMLS Holdings LLC
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Manager
Date:08/26/2025
C-LSH LLC
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Managing Member
Date:08/26/2025
M-LSH LLC
Signature:By: /s/ Keith A. Meister
Name/Title:Keith A. Meister, Managing Member
Date:08/26/2025
Casdin Capital, LLC
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Managing Member
Date:08/26/2025
Casdin Partners Master Fund, L.P.
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Managing Member of its General Partner
Date:08/26/2025
Casdin Partners GP, LLC
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Managing Member
Date:08/26/2025
Eli Casdin
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin
Date:08/26/2025
Keith A. Meister
Signature:By: /s/ Keith A. Meister
Name/Title:Keith A. Meister
Date:08/26/2025
Corvex Management LP
Signature:By: /s/ Keith A. Meister
Name/Title:Keith Meister, Managing Partner
Date:08/26/2025
Comments accompanying signature:
* This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

FAQ

How many shares of GeneDx (WGS) does Eli Casdin beneficially own according to the Schedule 13D/A?

Eli Casdin is reported to beneficially own 3,599,671 shares, representing 12.4% of the Class A shares outstanding based on 28,726,248 shares.

What percentage of GeneDx (WGS) does Keith A. Meister beneficially own?

Keith A. Meister is reported to beneficially own 3,630,826 shares, representing 12.5% of the Class A shares outstanding.

Do the reported holdings include any warrants or options for GeneDx (WGS)?

Yes. The reported holdings include 204,141 private placement warrants exercisable at $379.50 per share and various fully vested options and restricted stock units disclosed in the filing.

What source of funds was used to purchase the shares reported in the filing?

The funds for the purchase of the shares listed in Exhibit B came from the working capital of Casdin Partners Master Fund, L.P. No borrowed funds were used to purchase the Shares other than ordinary working capital borrowings.

Are there recent transactions by the reporting persons in the last 60 days?

Yes. The filing states that transactions in the securities of the issuer during the past sixty days are set forth in Exhibit B, and that all such transactions were carried out in open market transactions.
GeneDx Holdings Corp

NASDAQ:WGS

WGS Rankings

WGS Latest News

WGS Latest SEC Filings

WGS Stock Data

4.79B
25.36M
12.35%
110.61%
12.65%
Diagnostics & Research
Services-health Services
Link
United States
STAMFORD